Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01057251 · ClinicalTrials.gov registry record · Phase 4
Nebivolol in Patients With Systolic Stage 2 Hypertension
A Phase 4 study, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 4
- Development phase
- 433
- Enrollment target
NCT01057251 is a Phase 4 study that has completed, run by Forest Laboratories. The registered enrollment target is 433 participants.
The verdict
NCT01057251, a Phase 4 study, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 433 participants
- Enrollment target
Study Summary
The primary object of this study is to evaluate the efficacy and safety of 6 weeks of nebivolol monotherapy compared with placebo in patients with systolic stage 2 hypertension.
Interventions
- DRUG Placebo
- DRUG Nebivolol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 433 participants |
| Start Date | 2010-03 |
| Est. Completion | 2011-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01057251
The ClinicalTrials.gov registry entry for NCT01057251 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 433 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01057251 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01057251 about?
NCT01057251 is a clinical study titled "Nebivolol in Patients With Systolic Stage 2 Hypertension". The primary object of this study is to evaluate the efficacy and safety of 6 weeks of nebivolol monotherapy compared with placebo in patients with systolic stage 2 hypertension.
What is the current status of trial NCT01057251?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 433 participants. The study started on 2010-03. Estimated completion is 2011-01.
What interventions are being tested in trial NCT01057251?
The interventions under investigation include: Placebo (DRUG), Nebivolol (DRUG).
Who is sponsoring clinical trial NCT01057251?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.